Vantive (formerly Baxter Renal Care)

History

2026: Baxter dialysis systems found to be defective: They suddenly shut down

On January 14, 2026, the U.S. Food and Drug Administration (FDA) reported a problem with a set of tubes for Vantive dialysis systems (formerly a division of Baxter). The defect can lead to interruption of therapy and harm to the health of patients. Read more here.

2023

Spin-off to new Vantive company

On July 25, 2023, Baxter announced the spin-off of a technology business to treat kidney disease into a new company called Vantive.

After performing all necessary procedures and asset transfers, Vantive is expected to focus solely on kidney therapy. This approach will improve operational efficiency and help in strengthening market positions. The CEO of the new structure will be Chris Toth, executive vice president and president of the Kidney Care group at Baxter.

Baxter announces spin-off of technology business to treat kidney disease to new company

The creation of Vantive reflects the unwavering commitment of our dedicated employees to patients and our commitment to helping them lead full and meaningful lives. We intend to continue working with the renal and critical care communities as part of a program to transform care globally, "said Toth.

Vantive will continue the company's nearly 70-year history of treating kidney disease, Baxter said. Every year, Baxter serves over 1 million patients in more than 70 countries. Vantive will continue to focus on "meaningful changes in kidney care through innovative technologies, digital services and related services." As an independent organization with its own investment priorities and separate management, Vantive will have more opportunities to grow and innovate. Later, the new company will present its corporate logo and corporate symbols. Vantive intends to maintain partnerships with health care providers and clinicians around the world. It is planned to complete the allocation in 2024 - until then, the structure will continue to function as a division of Kidney Care as part of Baxter.^[1]

Creating a Company

On January 6, 2023, healthcare company Baxter announced plans to reorganize the business. The Renal Care and Acute Therapies units will be spun off into a stand-alone public structure.

These groups specialize in products for the treatment of kidney disease. These are, in particular, dialysis machines, consumables, related services and other equipment. In 2021, the volume of sales of these divisions on a global scale amounted to about $5 billion. Renal Care and Acute Therapies solutions help treat millions of patients in more than 70 countries around the world.

Healthcare company Baxter announces plans to open Renal Care unit

It is noted that the reorganization is aimed at significantly improving operational efficiency, improving long-term results, accelerating innovation and creating additional value for all stakeholders. The new company is expected to benefit from its existing product range, broad geography of presence and service capabilities. As a stand-alone entity with its own investment priorities and improved governance, the company will have higher potential for growth and innovation.

We are at a tipping point in Baxter's ongoing transformation journey. The healthcare landscape has never been more dynamic. These fundamental changes are necessary to ensure future development and innovation at the level that we demand of ourselves in the implementation of the mission to save and maintain lives, "said Jose E. Almeida, Chairman of the Board, President and Executive Director of Baxter.

Thus, Baxter followed the path of Medtronic, which in May 2022 announced a joint venture with dialysis giant DaVita. It is planned to complete the formation of a new company based on the assets of Renal Care and Acute Therapies within 12-18 months.^[2]

Notes